Search Instructions:
* Filter the ENTIRE resource library: Choose a OR a to sort all resources.
* Choose Search Items : to filter one collection or perform complex queries.
* Choose Browse by Topic to search by one or more Topics.
Browse Items (92 total)
-
Creator: Li, L., L. B. Robinson, R. Patel, A. B. Landman, X. Fu, E. S. Shenoy, D. M. Hashimoto, A. Banerji, P. G. Wickner, U. Samarakoon, C. M. Mancini, Y. Zhang, and K. G. Blumenthal.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-10-01
Description: Allergic history in individuals with confirmed anaphylaxis to a messenger RNA (mRNA) COVID-19 vaccine is common. However, the risk factors for allergy symptoms after receiving the vaccine are unknown. -
Creator: Bar-On, Yinon M., Yair Goldberg, Micha Mandel, Omri Bodenheimer, Laurence Freedman, Nir Kalkstein, Barak Mizrahi, Sharon Alroy-Preis, Nachman Ash, Ron Milo, and Amit Huppert.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-10-07
Description: On July 30, 2021, the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) was approved in Israel for persons who were 60 years of age or older and who had received a second dose of vaccine at least 5… -
Creator: Xia, ShengLi, YunTao Zhang, YanXia Wang, Hui Wang, YunKai Yang, George Fu Gao, WenJie Tan, GuiZhen Wu, Miao Xu, ZhiYong Lou, WeiJin Huang, WenBo Xu, BaoYing Huang, Wei Wang, Wei Zhang, Na Li, ZhiQiang Xie, Xiujuan Zhu, Ling Ding, WangYang You, YuXiu…
Subject: Research
Item Type: Publication
Date Last Updated: 2021-09-15
Description: Although SARS-CoV-2 infection often causes milder symptoms in children and adolescents, young people might still play a key part in SARS-CoV-2 transmission. An efficacious vaccine for children and adolescents could therefore assist pandemic control.… -
Creator: Barda, Noam, Noa Dagan, Yatir Ben-Shlomo, Eldad Kepten, Jacob Waxman, Reut Ohana, Miguel A. Hernán, Marc Lipsitch, Isaac Kohane, Doron Netzer, Ben Y. Reis, and Ran D. Balicer.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-08-25
Description: Preapproval trials showed that messenger RNA (mRNA)–based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet these trials were subject to size and patient-mix limitations. An evaluation of the… -
Creator: Kamar, Nassim, Florence Abravanel, Olivier Marion, Chloé Couat, Jacques Izopet, and Arnaud Del Bello.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-06-23
Description: A weak immune response to two doses of vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been observed in recipients of solid-organ transplants. -
Creator: the ENSEMBLE Study Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-06-10
Description: The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in a prefusion-stabilized conformation. -
Creator: Daniel, William, Marc Nivet, John Warner, and Daniel K. Podolsky.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-05-20
Description: Emergency use authorizations for two messenger RNA (mRNA) vaccines — the BNT162b2 vaccine (Pfizer–BioNTech) and the mRNA-1273 vaccine (Moderna) — marked important milestones in efforts to respond to the coronavirus disease 2019 (Covid-19) pandemic.…Example only: NETEC provides this item for reference purposes but does not endorse its content. Newer versions may be in place at the providing institution.
-
Creator: Sadoff, Jerald, Mathieu Le Gars, Georgi Shukarev, Dirk Heerwegh, Carla Truyers, Anne M. de Groot, Jeroen Stoop, Sarah Tete, Wim Van Damme, Isabel Leroux-Roels, Pieter-Jan Berghmans, Murray Kimmel, Pierre Van Damme, Jan de Hoon, William Smith, Kathryn…
Subject: Research
Item Type: Publication
Date Last Updated: 2021-05-13
Description: Efficacious vaccines are urgently needed to contain the ongoing coronavirus disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A candidate vaccine, Ad26.COV2.S, is a recombinant,… -
Creator: Shaw, Robert H., Arabella Stuart, Melanie Greenland, Xinxue Liu, Jonathan S. Nguyen Van-Tam, and Matthew D. Snape.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-05-12
Description: There is significant international interest in heterologous prime-boost COVID-19 vaccination to mitigate against supply shocks or shortages that might otherwise reduce the speed of vaccine roll-out. Additionally, in light of changing recommendations… -
Creator: Scully, Marie, Deepak Singh, Robert Lown, Anthony Poles, Tom Solomon, Marcel Levi, David Goldblatt, Pavel Kotoucek, William Thomas, and William Lester.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-04-16
Description: The mainstay of control of the coronavirus disease 2019 (Covid-19) pandemic is vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Within a year, several vaccines have been developed and millions of doses delivered.…